Priscilla F. Mcauliffe, MD, PhD
Advertisement
Articles by Priscilla F. Mcauliffe, MD, PhD
Such a systematic review of the current status of mTOR inhibitors in the treatment of breast cancer demonstrates holes in our knowledge of the role of the tumor, the host, and metabolic factors in breast cancer progression.
Advertisement
Latest Updated Articles
- How to Maximize the Potential of mTOR Inhibitors in Breast Cancer-More Questions Than Answers
Published: January 15th 2013 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
New CAR T-Cell Therapy Earns FDA Breakthrough Status in T-Cell Malignancies
2
Median OS Not Yet Reached With New Immunotherapy Combo in 2L Glioblastoma
3
FDA Accepts NDA for Gedatolisib in HR+/HER2–, PIK3CA Wild-Type Breast Cancer
4
FDA Issues Guidance on MRD, CR Outcomes for Multiple Myeloma Approvals
5